Treatment of Pharyngitis and Tonsillitis with Cefprozil: Review of Three Multicenter Trials
Clicks: 111
ID: 114778
1992
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
111 views
11 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #715 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract. Cefprozil is a new oral cephalosporin with an in vitro spectrum of activity that includes group A β-hemolytic streptococci (Streptococcus pyogenes).
| Reference Key |
m.1992clinicaltreatment
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | McCarty, James M.;Renteria, Antonio; |
| Journal | clinical infectious diseases |
| Year | 1992 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.